Olmesartan Medoxomil/Amlodipine Ascend (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil/amlodipine is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

• Hypertension: provides additive blood pressure reduction by combining an angiotensin II receptor blocker with a calcium‑channel blocker.
• High cardiovascular risk patients: helps achieve target blood pressure when monotherapy is insufficient.
• Elderly patients with hypertension: offers once‑daily oral control with a favorable tolerability profile.

• The combination pairs olmesartan medoxomil, an angiotensin II receptor blocker that prevents angiotensin II from binding to AT1 receptors, with amlodipine, a dihydropyridine calcium‑channel blocker that relaxes vascular smooth muscle by inhibiting calcium influx. Together they produce complementary vasodilation, lowering systemic vascular resistance and arterial pressure.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema
• Headache
• Flushing
• Fatigue
• Nasal congestion

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Hepatic enzyme elevation
• Acute kidney injury
• Heart block or severe bradycardia
• Allergic skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal impairment: adjust dose or monitor renal function regularly.
• Hepatic disease: use with caution and observe liver enzymes.
• Electrolyte disturbances: check potassium and sodium levels.
• Concomitant diuretics: monitor for excessive blood pressure fall.
• Pregnancy: contraindicated in the second and third trimesters.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Olmesartan medoxomil/amlodipine may interact with several drug classes; careful review of the medication list is essential.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal dysfunction.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase amlodipine exposure.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Potassium‑sparing diuretics or supplements: monitor serum potassium.
• Lithium: may increase lithium levels, requiring serum monitoring.
• Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk.
• Alcohol: may enhance hypotensive effects.